Skip to content
You are now leaving https://www.ionispharma.com to visit

New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease

Patients treated with AKCEA-APO(a)-L Rx received pre-specified endpoints for Lp(a) levels with favorable safety and tolerability profile Global Lp(a)HORIZON Phase 3 cardiovascular outcomes study underway BOSTON and CARLSBAD, Calif. , Jan. 02, 2020 (GLOBE NEWSWIRE) — Akcea Therapeutics, Inc.